Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onconova Appoints CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Onconova Appoints CEO

Dr. Fruchtman replaces Dr. Ramesh Kumar, who will transition to an advisory role

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dr. Steven Fruchtman has been named chief executive officer and a member of the board of directors, Onconova Therapeutics, Inc. Dr. Fruchtman has served as president of Onconova since June 2018, and originally joined the company in January 2015 as chief medical officer. Previously, he held senior leadership positions in pharmaceutical and biotechnology companies and academia. Dr. Fruchtman replaces Dr. Ramesh Kumar, who will transition to an advisory role for the company.
 
“Steve is the right leader for Onconova at this time. He has been instrumental to the Company’s progress thus far and his proven track record in drug development will continue to serve the Company well as it advances the Phase III-stage rigosertib programs toward approval and commercialization. The Board thanks Ramesh for his leadership and contributions to Onconova, and for positioning Onconova to reach critical upcoming milestones. We view Steve, and the recently expanded executive team that he has assembled, as poised to achieve clinical progress and business development objectives,” said Michael Hoffman, chairman of the Onconova Board of Directors.
 
Dr. Fruchtman has extensive industry experience in clinical research in MDS, hematologic malignancies, and solid tumors. He served with increasing leadership responsibilities at Ortho Biotech, Novartis, and biotechnology companies leading to successful clinical trial completion and regulatory approvals for a number of new chemical entities in various malignancies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters